The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells

Gynecologic Oncology

Volumn 118, Issue 1, 2010, Pages 64-68

  Cadron, Isabelle ^a   Van Gorp, Toon ^a   Mihalyi, Attila ^a   Luyten, Catherina ^a   Drijkoningen, Katrien ^a   Amant, Frederic ^a   Leunen, Karin ^a   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biomarker; CA 125; Enzastaurin; Ovarian cancer; OVCAR 3 cells

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; ENZASTAURIN; PACLITAXEL;

ANTIGEN EXPRESSION; ARTICLE; BIOSYNTHESIS; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL LYSATE; CHEMOLUMINESCENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; LUMINESCENCE; OVARY CANCER; PRIORITY JOURNAL; SUPERNATANT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CA-125 ANTIGEN; CARBOPLATIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 77953286369     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.008     Document Type: Article

References (17)

1. Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L., Baily S.N., et al. The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl) suppresses signalling through the AKT pathway, induces apoptosis and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 16 (2005) 7462-7469
2. Rizvi M.A., Ghias K., Davies K.M., Ma C., Weinberg F., Munshi H.G., et al. Enzastaurin (LY317615HCl), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 5 7 (2006) 1783-1789
3. Querfeld C., Rizvi M.A., Kuzel T.M., Guitart J., Rademaker A., Sabharwal S.S., et al. The selective protein kinase Cβ inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Investig Dermatol 126 (2006) 1641-1647
4. Beck E.P., Moldenhauer A., Kiesewetter F., Jäger W., Wildt L., and Lang N. CA125 production and release by ovarian cancer cells in vitro. Int J Biol Markers 13 4 (1998) 200-206
5. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 14 (2004) 2954-2963
6. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21 1 (1999) 64-65
7. Schöndorf T., Gohring U.J., Roth G., Middel I., Becker M., Moser N., et al. Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients. Eur J Clin Investig 33 (2003) 256-260
8. Rustin G.J. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21 10 Suppl (May 15 2003) 187-193
9. Marth C., Zeimet A.G., Böck G., and Daxenbichler G. Modulation of tumor marker CA125 expression in cultured ovarian carcinoma cells. Eur J Cancer 28A (1992) 2002-2006
10. Zeimet A.G., Offner F.A., Marth C., Heim K., Feichtinger H., Daxenbichler G., et al. Modulation of CA125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 17 (1997) 3129-3132
11. Marth C., Egle D., Auer D., Rössler J., Zeimer A.G., Vergote I., et al. Modulation of CA125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab. Gynaecol Oncol 105 3 (June 2007) 716-721
12. Marth C., Zeimet A.G., Widschwendter M., Ludescher C., Kaern J., Tropé C., et al. Paclitaxel and docetaxel dependent activation of CA125 expression in human ovarian carcinoma cells. Cancer Res 57 (September 1997) 3818-3822
13. Van der Burg M.E.L., Myles J.D., Hoskins P.J., Ten Bokkel H.W.W., and Eisenhauer E. CA 125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. Eur J Cancer 29A (1993) 133
14. Paulsen T., Marth C., Kaern J., Nustad K., Kristensen G.B., and Trope C. Effects of paclitaxel on CA 125 serum levels in ovarian cancer patients. Gynaecol Oncol 76 (2000) 326-330
15. Mearl M.L., Yashar C.M., Johnston C.M., Reynolds K., and Roberts J.A. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gynaecol Oncol 53 (1994) 339-343
16. Bridgewater J.A., Nelstrop A.E., Rustin G.J.S., Gore M.E., McGuire W.P., and Hoskins W.J. Comparison of standard and CA125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. JCO 17 (1999) 501-508
17. Davelaar J.M.G., Bonfrer R.A., Verstraeten W.W., Davelaar, Bonfrer J.M.G., Verstraeten R.A., et al. CA125, A valid marker in ovarian carcinoma patients treated with paclitaxel?. EM Cancer 78 (1996) 118-127